GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » Days Sales Outstanding

VSTM (Verastem) Days Sales Outstanding : 0.00 (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Days Sales Outstanding?

Verastem's average Accounts Receivable for the three months ended in Dec. 2024 was $0.20 Mil. Verastem's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for Verastem's Days Sales Outstanding or its related term are showing as below:

VSTM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.18   Med: 18.45   Max: 96.96
Current: 96.96

During the past 13 years, Verastem's highest Days Sales Outstanding was 96.96. The lowest was 4.18. And the median was 18.45.

VSTM's Days Sales Outstanding is ranked worse than
66.35% of 847 companies
in the Biotechnology industry
Industry Median: 72.4 vs VSTM: 96.96

Verastem's Days Sales Outstanding stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).


Verastem Days Sales Outstanding Historical Data

The historical data trend for Verastem's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Days Sales Outstanding Chart

Verastem Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.70 67.12 38.45 - 7.30

Verastem Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 46.66 - -

Competitive Comparison of Verastem's Days Sales Outstanding

For the Biotechnology subindustry, Verastem's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Verastem's Days Sales Outstanding falls into.


;
;

Verastem Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Verastem's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0 + 0.2) / 1 ) / 10*365
=0.2 / 10*365
=7.30

Verastem's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (0.2 + 0.2) / 2 ) / 0*365 / 4
=0.2 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verastem  (NAS:VSTM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Verastem Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Verastem's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem Business Description

Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Executives
Daniel Calkins officer: Vice President of Finance C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Dan Paterson officer: Chief Operating Officer 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson director C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur director 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104